In pursuit of novel anticancer agents with enhanced potency and selectivity, a new series of quinazoline-based derivatives was rationally designed, synthesized, and biologically evaluated as potential DNA intercalators and topoisomerase II (Topo II) inhibitors. Building upon a previously identified lead compound (6), s...
Amr S. Helmy, Mamdouh F. A. Mohamed, I. Eissa et al.· Bioorganic chemistry (Print)· 0 citations
Experimental and computational findings identify compound 17 as a promising and mechanistically well‐characterized VEGFR‐2 inhibitor, warranting further in vivo investigation.
Hazem Elkady, Aisha A. Alsfouk, E. Elkaeed et al.· Archiv der Pharmazie· 0 citations
This integrated study pinpointed ACEB-Cl as a promising VEGFR-2targeted anticancer lead compound with strong inhibitory potency, and a clearly defined mechanism of action, supporting its progression for further improvement.
A. Metwaly, I. Eissa, Walid E. Elgammal et al.· Journal of Computational Bio...· 0 citations
Findings identify compound 7e as a promising VEGFR-2-targeted anticancer lead with strong enzymatic inhibition, potent cytotoxicity, and a well-supported mechanistic profile integrating experimental and computational evidence.
A. Metwaly, Walid E. Elgammal, I. Eissa et al.· RSC Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.